Pharmaceutical

Antengene’s multiple myeloma therapy receives approval in Hong Kong

Antengene has received approval in Hong Kong for a new drug application (NDA) for Xpovio (selinexor) to treat multiple myeloma (R/R MM).

Jul 17, 2023 - 20:00
Antengene’s multiple myeloma therapy receives approval in Hong Kong
Antengene has received approval in Hong Kong for a new drug application (NDA) for Xpovio (selinexor) to treat multiple myeloma (R/R MM).
Read the original article

Tags:

Previous Article

Australian CAI unveils new facility for cancer therapy development

Next Article

Vivoryon issues updates on its Alzheimer’s therapy programme

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

AstraZeneca completes Gracell Biotechnologies acquisiti...

Feb 24, 2024

After Amylyx ALS trial failure, patients share disappointment and fear — but some hope

After Amylyx ALS trial failure, patients share disappoi...

Mar 13, 2024

Oral Solid Dose Manufacturing Companies in the Pharmaceutical Industry

Oral Solid Dose Manufacturing Companies in the Pharmace...

Sep 26, 2024